FDA granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.
When Robert A. Winn was named director of the University of Illinois Cancer Center in 2015, he knew that the skills required to be a successful cancer center director were very different from the skills he drew upon to be a successful scientist. So, he formed an informal, personal mentorship team.
